NYSEAM:PLX - Post by User
Post by
skyhigh123on Mar 14, 2018 11:18am
164 Views
Post# 27713223
?????
????? Protalix: It's Time To Sell
Summary
Protalix announced the results of their phase 2 open label trial of OPRX-106 for the treatment of Ulcerative Colitis on March 13.
The results are positive, but there is an important omission.
The company did not address why 6 out of 24 (25%) enrolled patients did not complete the trial.
Like PRX-110's CF trial, OPRX-106's UC data only provides early evidence of efficacy.
If partnerships are not secured, dilution risks are most likely to fund further operations.